Skip to Content

Other Cancer Trials

NCI 9671: Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients Who Are Exceptional Responders
Aims: The purpose of this study is to see why some patients respond well to treatment that didn't work for most other patients with this disease.  The study will be collecting tissue.
Diagnosis: any solid tumor
Principal Investigator: Gustavo Rodriguez, MD
IRB Approval Number: 
Sponsor: National Cancer Institute
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

Janssen 39039039STM4001: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Sytemic Cancer Therapy and at High Risk for Venous Thromboembolism
Aims: The purpose of this study demonstrate that Rivaroxaban is superior to placebo in reducing the risk of blood clots in patients that are at a high risk of developing them.
Diagnosis: Lung Cancer, Pancreatic Cancer, Gastric Cancer, and any Gynecological cancer
Principal Investigator: Afonso Tafur, MD
IRB Approval Number: EH15-402
Sponsor: Janssen Scientific Affairs
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin in VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Aims: The purpose of this study is gather information oral anti-coagulants versus the usual care of low-molecular weight heparin/warfain in the treatment of blood clots.
Diagnosis: Any cancer except leukemia
Principal Investigator: Afonso Tafur, MD
IRB Approval Number: EH17-042
Sponsor: Alliance Foundation Trials
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

RU221501I, A Phase III Randomized, Open label Study Evaluating the Safety of Apixaban in Subjects wtih Cancer Related Venous Thromboembolism
Aims: Both Apixaban and Dalteparin are approved by the FDA to treat blood clots. However, only Dalteparin is approved for blood clots in cancer patients. This study will see if Apixaban will treat and prevent blood clots in patients with cancer.
Diagnosis: Any cancer
Principal Investigator: Afonso Tafur, MD

IRB Approval Number: EH16-087
Sponsor: Bristol Myers-Squibb
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

EAY131: Molecular Analysis for Therapy Choice (MATCH)
Aims: This study will look at assigning treatment for patients whose cancer has become worse after standard treatment. Patients will have a genomic analysis of their tumor which will direct appropriate targeted therapy.
Diagnosis: any solid tumor
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH15-387
Sponsor: ECOG-ACRIN/NCI 
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes (limited)